Senate File 307 - Introduced
SENATE FILE 307
BY ALONS
A BILL FOR
1 An Act relating to step therapy protocols and interchangeable
2 biosimilars.
3 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
TLSB 2200XS (4) 90
ko/rn
 S.F. 307
1 Section 1. Section 514F.7, subsection 1, Code 2023, is
2 amended by adding the following new paragraphs:
3 NEW PARAGRAPH. 0b. “Biological product” means the same as
4 defined in section 155A.3.
5 NEW PARAGRAPH. 00b. “Biosimilar” means the same as defined
6 in 42 U.S.C. §262.
7 NEW PARAGRAPH. 0i. “Interchangeable” means the same as
8 defined in 42 U.S.C. §262.
9 NEW PARAGRAPH. 00i. “Interchangeable biological product”
10 means the same as defined in section 155A.3.
11 Sec. 2. Section 514F.7, subsection 4, paragraph a, Code
12 2023, is amended to read as follows:
13 a. Prevent a health carrier, health benefit plan, or
14 utilization review organization from requiring a covered person
15 to try a prescription drug with the same generic name and
16 demonstrated bioavailability, or a biological product that
17 is an interchangeable biological product pursuant to section
18 155A.32, or an interchangeable biosimilar prior to providing
19 coverage for the equivalent branded prescription drug.
20 EXPLANATION
21 The inclusion of this explanation does not constitute agreement with
22 the explanation’s substance by the members of the general assembly.
23 This bill relates to step therapy protocols and
24 interchangeable biosimilars.
25 Under current law, a health carrier, health benefit plan, or
26 utilization review organization may require a covered person
27 (person) to try a prescription drug (drug) with the same
28 generic name and demonstrated bioavailability, or a biological
29 product that is an interchangeable biological product, prior to
30 providing coverage for an equivalent branded drug. The bill
31 allows a health carrier, health benefit plan, or utilization
32 review organization to also require a person to try an
33 interchangeable biosimilar prior to providing coverage for an
34 equivalent branded drug. “Biosimilar” and “interchangeable”
35 are defined in the bill.
LSB 2200XS (4) 90
-1- ko/rn 1/1


Statutes affected:
Introduced: 514F.7